Visiomed Group SA
PAR:ALVMG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (242.3), the stock would be worth €0.17 (0% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 242.3 | €0.17 |
0%
|
| 3-Year Average | 242.3 | €0.17 |
0%
|
| Industry Average | 20.6 | €0.01 |
-92%
|
| Country Average | 13.2 | €0.01 |
-95%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
€55.7m
|
/ |
Jan 2024
€230k
|
= |
|
|
€55.7m
|
/ |
Dec 2024
€4.1m
|
= |
|
|
€55.7m
|
/ |
Dec 2025
€11.4m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| FR |
|
Visiomed Group SA
PAR:ALVMG
|
50.8m EUR | 242.3 | 56.3 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
161B USD | 19.2 | 25.7 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
160.3B USD | 52.2 | 56.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.2B USD | 23.9 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.2B USD | 18.5 | 22.8 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
88.3B USD | 24.4 | 30.5 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
42.9B EUR | 16 | 20.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD | 25.7 | 43.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.4B USD | 33.5 | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.6B USD | 17 | 25.4 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
32.9B USD | 13.8 | 15.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 9.5 |
| Median | 13.2 |
| 70th Percentile | 17.5 |
| Max | 1 862.3 |
Other Multiples
Visiomed Group SA
Glance View
Visiomed Group SA engages in the development and distribution of healthcare products and services. The company is headquartered in Puteaux, Ile-De-France. The company went IPO on 2011-07-05. The firm is primarily engaged in the design, manufacture and marketing of medical electronics. The company develops and markets health products in the fields of medical and well-being self-diagnosis to provide non-drug prevention and treatment solutions. The firm's product portfolio comprises MyThermo, an infrared contact-less medical thermometer; MyTension, an automatic blood pressure and pulse monitors; MyOxy, a finger pulse oximeter; MyECG, a pocket electrodiogram; MyGluco, a blood sugar meter; My Coach, a health and fitness coach, and Epiderm, a telemedicine dermatology mobile application, among others. The firm serves pharmacies, health professionals, hospitals, clinics and retirement homes. The company also offers connected solutions and COVID devices such as deconfinement kits, masks, filter cushion, serological tests etc. The Company’s subsidiaries include ThermoFlash and BewellConnect.
